TA-1801 is a hypolipidemic agent; it inhibits platelet aggregation in vitro; it reduces serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dietary dose of 0.05% in normal rats, and exhibits approximately 10-fold greater activity in hereditary hyperlipidemic rats (THLR/1) compared to normal rats.